La vendita allo scoperto per Evogene dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Evogene. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Evogene (NASDAQ:EVGN) Azioni, Report sulle vendite allo scoperto

Evogene

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.

Evogene Ltd

General

EVGN

Evogene shares are trading higher after the company announced a collaboration with Google Cloud to pioneer a generative AI foundation model for novel small molecule design.

The collaboration has the power to foster breakthroughs in small molecule innovation for life science-based products
REHOVOT, Israel, Oct. 31, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced a collaboration with Google Cloud to develop a cutting-edge foundation model for generative small molecule de novo design, propelling Evogene's ChemPass AI tech-engine to new levels of innovation. ChemPass AI is a computational technology platform that directs and accelerates the discovery and development of novel products based on small molecules. This groundbreaking initiative seeks to advance the discovery and development of novel small molecules for drug development, sustainable crop protection, and other innovative products across a wide range of life-science industries.

News

GOOG

GOOGL

Evogene Announces Collaboration With Google Cloud To Pioneer Generative AI Foundation Model For Novel Small Molecule Design, Leveraging Evogene's Deep Expertise In Computational Predictive Biology And Google Cloud's Leadership In AI And Machine Learning

Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable&nbsp;aquaculture and biotech and Evogene Ltd. ("Evogene") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>)(TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, together with Ben-Gurion University (BGU), a renowned Israeli academic research institution, announced receiving an approval from IIA for a second year grant to continue developing &nbsp;CRISPR technology for crustaceans, following a successful first year.
&nbsp;
The collaboration aims to provide a sustainable solution to existing limitations in gene editing for non-model organisms with sparse genomic data and protocols, focusing on improving key traits such as growth rate, disease resistance, and environmental adaptation in crustaceans, targeting giant freshwater prawn, white leg shrimp and red swamp crayfish.
The global shrimp market size was USD 40.35 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.09% during the 2024-2032 period[1]. The global crayfish market is projected to grow at a CAGR of 31.5% between 2024 and 2032[2]. These growing markets increasingly emphasize the need to expand sustainable aquaculture, making the technology developed in the frame of the collaboration exceptionally relevant.
During the first year the partners successfully met the collaboration's planned goals. Evogene leveraged its advanced&nbsp;GeneRator AI&nbsp;tech-engine and provided predictions for optimal guide RNAs (gRNAs), through several novel features: utilization of un-annotated genomes (lacking gene models), consideration of natural DNA variance in gRNAs design, and off-target prediction to increase editing specificity. This allowed Watershed and BGU to successfully produce the first edited giant freshwater prawn&nbsp;(Macrobrachium rosenbergii) with a selected target trait of colored eye, post larvae at advanced life stages, thereby achieving the main milestone in the utilization of CRISPR technology in crustaceans.
In the second year, the collaboration's main target is to industrially scale-up CRISPR technology for giant freshwater prawn&nbsp;and expand the obtained application to the additional crustacean species, white leg shrimp (Litopenaeus vannamei) and red swamp crayfish (Procambarus clarkia). &nbsp;

Watershed and Evogene Receive Grant to Advance CRISPR Tech for Crustaceans, Targeting Sustainable Aquaculture

WIIM

Evogene shares are trading higher after the company announced its subsidiary received a grant from the Israel Innovation Authority to advance its program to develop a technology for the delivery of Ag-biologicals to agriculture.

. This patented technology, named 'MicroFermentor', is based on an innovative microbe formulation that enables the multiplication of beneficial bacteria directly on the plant, reducing application costs, extending shelf life, and prolonging the bacteria's viability after field application. The grant was awarded following positive initial microbe encapsulation and greenhouse validation experiments and will support the program's next phase of development toward commercialization.

Health Care

Lavie Bio, A Subsidiary Of Evogene Received A Grant From The Israel Innovation Authority To Advance Its Program To Develop A Technology For The Delivery Of Ag-biologicals To Agriculture

Lake Street analyst Ben Klieve maintains Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) with a Buy and lowers the price target from $30 to $12.

Price Target

Analyst Ratings

Lake Street Maintains Buy on Evogene, Lowers Price Target to $12

Offerings

Evogene Prices $5.5M Registered Direct Offering Of 1,692,308 Shares And Concurrent Private Placement

Evogene shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Earnings

Evogene Q2 2024 GAAP EPS $(1.06) May Not Be Comparable To $(0.12) Estimate, Sales $914.000K Beat $800.000K Estimate

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Evogene shares are trading lower after the company announced a 1-for-10 reverse share split.

Approximately 5,079,000 Ordinary Shares Outstanding Post-Split; Trading On Nasdaq Capital Market Begins July 25, 2024, And On Tel Aviv Stock Exchange Begins July 28, 2024

Stock Split

Reported Earlier, Evogene Announces 1-for-10 Reverse Share Split

More than one dozen novel microbes identified for row crops&nbsp;suffering from extreme weather conditions
TEL AVIV and REHOVOT, Israel, July 17, 2024 /PRNewswire/ -- ICL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICL#NYSE">ICL</a>) (TASE: ICL), a leading global specialty minerals company, and Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) (TASE: EVGN), today announced a significant milestone in their collaboration to develop bio-stimulant solutions for key row crops facing various abiotic stresses. By leveraging artificial intelligence (AI), Lavie Bio has computationally identified more than a dozen novel microbial candidates believed to have commercial viability as bio-stimulants for crops grown under extreme weather conditions, including drought.&nbsp; While this process can normally take several years, the collaboration achieved success within its first 12 months – thanks to Lavie Bio's proprietary Biology Driven Design (BDD) technology platform.

Biotech

ICL And Lavie Bio Leverage AI To Make Significant Advancement In Development Of Yield Increasing Bio-Stimulants

Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) (TASE: EVGN), is pleased to announce the commercial expansion of its bio-inoculant product, Yalos&trade;, to winter wheat, following successful trials. This expansion effectively doubles the potential market for Yalos&trade; compared to markets in which&nbsp;Lavie Bio&nbsp;already operates. Winter wheat growers across the US will have access to Yalos&trade; for the upcoming 2024-2025 season.
<img alt="Evogene" src="https://mma.prnewswire.com/media/1947468/Evogene.jpg" />
Winter wheat is one of the crucial crops in&nbsp;North America&nbsp;and globally, significantly contributing to the agricultural economy and food supply. The US is expected to produce about 1.28 billion bushels in 2024[1], with a market value, according to&nbsp;Lavie Bio&#39;s&nbsp;estimation, between&nbsp;$5-$10 billion&nbsp;annually. Introducing Yalos&trade; to this market offers substantial potential to capture market share by enhancing crop productivity and sustainability. To date,&nbsp;Lavie Bio&nbsp;has focused on the spring wheat market, along with durum and barley, which together form a smaller market compared to winter wheat.
During the successful field trials, Yalos&trade; has demonstrated enhanced early vigor, biomass, root and shoot development, nutrient availability, and feed quality in winter wheat. Yalos&trade; aims to reduce crop abandonment rates and increase farm productivity through advanced biological technologies.
In addition,&nbsp;Lavie Bio&nbsp;is expecting to expand Yalos&trade; into other key crops, such as soybean and canola, with ongoing field trials in&nbsp;North America&nbsp;and an expected commercial launch in 2025. The US soybean market size is estimated by&nbsp;Lavie Bio&nbsp;at approximately&nbsp;$56.2&nbsp;billion in 2024.

Lavie Bio Expands Yalos Bio-Inoculant to Winter Wheat Market, Doubling Potential Reach

Casterra Ag Ltd.,&nbsp;a subsidiary of Evogene Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) (TASE: EVGN), is a provider of an integrated solution for industrial-scale cultivation of castor plants based on its elite castor seed varieties, developed for bio-based industries including, biofuels &amp; biopolymers. Casterra is pleased to announce the receipt of an additional purchase order valued at&nbsp;~$440K&nbsp;from an existing customer. This order expands Casterra&#39;s operations into a new African country and solidifies Casterra&#39;s unique offering in the bio-fuel market.
Mr. Yoash Zohar, CEO of Casterra states: &quot;This additional order reflects the confidence in Casterra&#39;s capabilities and in our castor seed varieties, developed utilizing Evogene&#39;s&nbsp;GeneRator AI&nbsp;tech-engine and Casterra&#39;s advanced breeding methods, and marks a significant step in our expansion into&nbsp;Africa. We expect that our previously announced seed production, now totaling 900 tons, will more than support this order, which is expected to be completed by&nbsp;Q4&nbsp;2024, as well as earlier purchase orders received last year. Casterra remains committed to being a world leader in castor seed development and production and promoting sustainable biofuel production globally.&quot;&nbsp;
Casterra anticipates that the remaining revenue from castor seed orders received during 2023 and in 2024, which were not supplied to date (including the order described in today&#39;s PR), will be approximately&nbsp;~$8.4 million, reflecting a price adjustment due to late delivery of the order from 2023. Based on the planned production this year, Casterra expects to recognize revenues in this amount in the second half of 2024.
The global biodiesel market size was estimated at $36.48 billion&nbsp;in 2022 and it is expected to hit around $79.12 billion&nbsp;by 2032, expanding at a notable CAGR of&nbsp;8.1%&nbsp;from 2023 to 2032[1]. Biofuels offer significant advantages over conventional petrochemical fuels, presenting a renewable and biodegradable alternative with substantially lower negative environmental impact.&nbsp;Castor oil emerges as a standout non-fossil oil candidate due to its carbon-neutral and other properties making it compliant with tightening European regulatory standards.
Casterra&#39;s high oil-yielding varieties have been developed with traits which make the castor plants grown suitable for large scale farming on marginal soils in semi-arid conditions. Castor plants and the castor oil produced have the potential of becoming a major sustainable feedstock for the global bio-fuel industry &ndash; without competing with food crops over prime land.&nbsp;

Government

Regulations

Evogene Subsidiary Casterra Ag Expands into Africa with $440K Castor Seed Order

Biomica Announces Encouraging Initial Findings From Phase 1 Clinical Trial Of BMC128, Its Microbiome-Based Immuno-Oncology Candidate, In Combination With Nivolumab For Patients With NSCLC, Melanoma, Or RCC

Evogene Q1 2024 GAAP EPS $(0.08) Beats $(0.09) Estimate, Sales $4.190M Beat $3.500M Estimate

Evogene Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) (TASE: EVGN) announced on Thursday its financial results for the fourth quarter and full-year period ending December 31, 2023.
In the fourth quarter revenues amounted to $578 000, down 12% year-over-year. However, the Rehovot, Israel-based <a href="https://www.benzinga.com/cannabis">cannabis</a> company reported $5.6 million in revenue for 2023, representing a year-over-year increase of 237% from $1.7 million in 2022.
&#8220;The Evogene Group has experienced a transformative year with industry perception of our technology and products translating into growing collaborations with world-leading companies," Ofer Haviv, Evogene&#8217;s president and CEO, said in a press release.
Haviv praised the company's "collaboration momentum" referring to forged partnerships with Corteva, ICL, Syngenta and Baye, to name a few, via its subsidiaries Casterra Ag Ltd., AgPlenus Ltd., Biomica Ltd., and Lavie Bio Ltd. 
"These efforts not only validate our contributions but also bolster our financial position through various revenue streams, reflected in today&#8217;s reported revenues," Haviv added.
As for its Canonic Ltd. subsidiary that develops medical cannabis products based on decoding plant genetics for optimized therapeutic effect., Evogene said its reducing its investment in it as a &#8220;response to challenging market conditions in the medical cannabis sector.&#8221;
The company also said that it&#8217;s in advanced discussions regarding the potential transfer of Canonic&#8217;s operations to a third party. 
However, the completion and terms of such a transfer remain uncertain, Evogene said.
See also: <a href="https://www.benzinga.com/markets/cannabis/23/11/35828206/israeli-cannabis-company-reports-strong-q3-despite-geopolitical-challenges">Israeli Cannabis Company Reports Strong Q3 Despite Geopolitical Challenges</a>
<h3 class="wp-block-heading">Q4 2023 Financial Highlights</h3>
<ul>
<li>Gross profit totaled $180 000, down from $296 000 in the prior year's period.</li>
<li>Net financing income amounted to approximately $ 287,000, an increase from approximately $ 6,000 in the same period the previous year.</li>
<li>Total operating expenses amounted to $7.8 million, up from roughly $4 million in the same quarter of last year.</li>
<li>Net loss amounted to $7.3 million, an increase from $3.8 million in the same quarter of last year.</li>
</ul>
<h3 class="wp-block-heading">FY 2023 Financial Highlights</h3>
<ul>
<li>Gross profit totaled $3.9 million, up from $ 766,000 in the prior year's period.</li>
<li>Net financing income totaled approximately $521 000, compared to net financing expenses of approximately $2.8 million in the same period in the previous year.</li>
<li>Total operating expenses amounted to $30.4 million, up from roughly $27.7 million in the same quarter of last year.</li>
<li>Net loss amounted to roughly $26 million, down from around $3o million in the same quarter of last year.</li>
</ul>
<h3 class="wp-block-heading">Evogene&#8217;s Main Accomplishments In 2023</h3>
<ul>
<li>Partnership with Verb Biotics</li>
<li>Collaboration with Colors Farm and Ben Gurion University</li>
<li>€1.2 million ($1.2 million) EU Grant for Ag-Seed Division to develop oil-seed crops with enhanced CO2 assimilation and drought tolerance.</li>
</ul>
Now read: <a href="https://www.benzinga.com/markets/cannabis/23/08/33894969/israeli-cannabis-co-reports-solid-q2-performance-nearing-growth-targets">Israeli Cannabis Co. Reports Solid Q2 Performance, Nearing Growth Targets</a>
<h3 class="wp-block-heading">EVGN Price Action</h3>
Evogene's shares traded 4.43% lower at $0.8875 per share during the pre-market session on Thursday morning. 
The <a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a> is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at <a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">The Diplomat Beach Resort</a> will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Get your tickets now on </a><a href="http://bzcannabis.com" target="_blank" rel="noreferrer noopener">bzcannabis.com</a><a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener"> – Prices will increase very soon!</a>

Cannabis

Israeli Company Reports Record 2023 Revenue, Wants To Transition Cannabis Operations To 'Third Party'

Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 85.71 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $578.00 thousand.

Evogene Q4 EPS $(0.13) Beats $(0.14) Estimate, Sales $578.00K Beat $500.00K Estimate

AFCG

ALIM

AMTX

AOUT

ARBE

ARCT

ARHS

ASLE

ASPS

AVGO

BBAI

BBCP

BILI

BITF

BNED

BURL

CHMI

CIEN

CINT

CLAR

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

COOK

COST

CTOS

DBVT

DLTH

DOCU

DOMO

DSGR

DXPE

ELUT

EOLS

EYPT

FCEL

FNKO

GEVO

GIFI

GRND

GRNT

GWRE

HBIO

ISDR

JYNT

LCTX

LMNR

LOCO

LUMO

LVRO

METC

MGNX

MKFG

MRVL

NAPA

NCSM

NDLS

NEPH

NINE

ONCT

ONCY

OPFI

OPTN

OWLT

PBPB

PHAT

PMTS

PRCH

PowerShares Dynamic Industrials Sector Portfolio

PROF

PRTS

PSFE

RDVT

REAX

REFR

RWAY

SDPI

SGHT

Earnings Scheduled For March 7, 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Evogene (NASDAQ:<a href="https://investorplace.com/stock-quotes/evgn-stock-quote/">EVGN</a>) just reported results for the second quarter of 2024.<ul><li>Evogene reported earnings per share of -$1.06. This was below the analyst estimate for EPS of -12 cents.</li><li>The company reported revenue of $914,000.</li><li>This was 14.25% better than the analyst estimate for revenue of $800,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/evgn-stock-earnings-evogene-for-q2-of-2024/">EVGN Stock Earnings: Evogene Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EVGN Stock Earnings: Evogene Misses EPS, Beats Revenue for Q2 2024

Evogene (EVGN) has released an update. Evogene Ltd. has released its unaudited interim consolidated financial statements, revealing a decrease in c...

Evogene Ltd. Reports Mid-Year Financial Dip

Evogene (EVGN) has released an update. Evogene Ltd. announced significant changes to its management team, including the departure of Chief Technolo...

Evogene Announces Major Management Restructuring

Evogene (EVGN) announced a collaboration with Google Cloud (GOOG, GOOGL) to develop a cutting-edge foundation model for generative small molecule d...

Evogene announces collaboration with Google Cloud

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Evogene (NASDAQ:<a href="https://investorplace.com/stock-quotes/evgn-stock-quote/">EVGN</a>) just reported results for the second quarter of 2024.<ul><li>Evogene reported earnings per share of -$1.06. This was below the analyst estimate for EPS of -12 cents.</li><li>The company reported revenue of $914,000.</li><li>This was 14.25% better than the analyst estimate for revenue of $800,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/evgn-stock-earnings-evogene-for-q2-of-2024/">EVGN Stock Earnings: Evogene Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Press Releases

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Evogene Reports Second Quarter 2024 Financial Results

Small Cap

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement

Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology

Commodities

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

"The Future is Bright: Peraso Inc. (NASDAQ: PRSO) Expands Technology for Tactical Applications in High-Demand Industries – More Stocks Inside…"

Evogene Schedules Third Quarter 2024 Financial Results Release

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Comments

Evogene

Vendite allo scoperto

Evogene (NASDAQ:EVGN) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO